Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
In the latest session, Legend Biotech Corp ADR (NASDAQ: LEGN) closed at $27.15 down -3.62% from its previous closing price of $28.17. In other words, the price has decreased by -$3.62 from its previous closing price. On the day, 6.27 million shares were traded. LEGN stock price reached its highest trading level at $29.39 during the session, while it also had its lowest trading level at $25.71.
Ratios:
For a deeper understanding of Legend Biotech Corp ADR’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.80 and its Current Ratio is at 2.86. In the meantime, Its Debt-to-Equity ratio is 0.41 whereas as Long-Term Debt/Eq ratio is at 0.26.
Upgrades & Downgrades
In the most recent recommendation for this company, Cantor Fitzgerald on October 07, 2025, initiated with a Overweight rating and assigned the stock a target price of $40.
On October 08, 2024, Redburn Atlantic started tracking the stock assigning a Buy rating and target price of $86.
On June 17, 2024, Truist started tracking the stock assigning a Buy rating and target price of $88.Truist initiated its Buy rating on June 17, 2024, with a $88 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 17 ’25 when GenScript Corporation bought 203,586 shares for $30.29 per share.
Casey Patrick John bought 1,000 shares of LEGN for $33,285 on Sep 26 ’25. On Sep 24 ’25, another insider, Huang Ying, who serves as the Officer of the company, bought 1,370 shares for $33.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LEGN now has a Market Capitalization of 5014321664 and an Enterprise Value of 9446290432. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.51 while its Price-to-Book (P/B) ratio in mrq is 4.96. Its current Enterprise Value per Revenue stands at 10.391 whereas that against EBITDA is -52.12.
Stock Price History:
The Beta on a monthly basis for LEGN is 0.13, which has changed by -0.33842182 over the last 52 weeks, in comparison to a change of 0.09654534 over the same period for the S&P500. Over the past 52 weeks, LEGN has reached a high of $45.30, while it has fallen to a 52-week low of $27.34. The 50-Day Moving Average of the stock is -15.10%, while the 200-Day Moving Average is calculated to be -21.00%.
Shares Statistics:
For the past three months, LEGN has traded an average of 1.35M shares per day and 2072140 over the past ten days. A total of 184.69M shares are outstanding, with a floating share count of 180.91M. Insiders hold about 2.05% of the company’s shares, while institutions hold 44.44% stake in the company. Shares short for LEGN as of 1761868800 were 10772670 with a Short Ratio of 7.99, compared to 1759190400 on 9351983. Therefore, it implies a Short% of Shares Outstanding of 10772670 and a Short% of Float of 11.16.
Earnings Estimates
A detailed examination of Legend Biotech Corp ADR (LEGN) is currently in progress, with 7.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.04, with high estimates of -$0.04 and low estimates of -$0.04.
Analysts are recommending an EPS of between -$0.82 and -$1.59 for the fiscal current year, implying an average EPS of -$1.11. EPS for the following year is $0.54, with 8.0 analysts recommending between $0.99 and $0.08.
Revenue Estimates
A total of 11 analysts believe the company’s revenue will be $318.45M this quarter.It ranges from a high estimate of $368.26M to a low estimate of $302.15M. As of. The current estimate, Legend Biotech Corp ADR’s year-ago sales were $186.52MFor the next quarter, 11 analysts are estimating revenue of $332.02M. There is a high estimate of $378.75M for the next quarter, whereas the lowest estimate is $301.83M.
A total of 14 analysts have provided revenue estimates for LEGN’s current fiscal year. The highest revenue estimate was $1.09B, while the lowest revenue estimate was $1.01B, resulting in an average revenue estimate of $1.04B. In the same quarter a year ago, actual revenue was $627.24MBased on 14 analysts’ estimates, the company’s revenue will be $1.57B in the next fiscal year. The high estimate is $1.91B and the low estimate is $1.37B.
